

No. 14-

IN THE
Supreme Court of the United States

STIEFEL LABORATORIES, INC.,
AND CHARLES STIEFEL,

Petitioners,

v.

TIMOTHY FINNERTY,

Respondent.

ON PETITION FOR A WRIT OF CERTIORARI TO THE UNITED
STATES COURT OF APPEALS FOR THE ELEVENTH CIRCUIT

PETITION FOR A WRIT OF CERTIORARI

TODD D. WOZNIAK
GREENBERG TRAURIG, LLP
Terminus 200
3333 Piedmont Road NE
Suite 2500
Atlanta, Georgia 30305
(678) 553-2100

ELLIOT H. SCHERKER
Counsel of Record
HILARIE BASS
DAVID A. COULSON
BRIGID F. CECI SAMOLE
GREENBERG TRAURIG, P.A.
333 S.E. Second Avenue
Suite 4400
Miami, Florida 33131
(305) 579-0579
scherkere@gtlaw.com

Counsel for Petitioners

256915



COUNSEL PRESS

(800) 274-3321 • (800) 359-6859

QUESTION PRESENTED

The Eleventh Circuit held that, because a jury could have determined that the defendant corporation owed a duty to “update” a former employee with respect to a statement that was truthful and accurate when made, by providing information to the former employee regarding subsequent preliminary merger discussions, the corporation was properly held liable for securities fraud. The question presented is whether Section 10(b) of the Securities Exchange Act and Rule 10b-5 impose a duty on a corporation to “update” prior truthful statements.

**PARTIES TO THE PROCEEDING
AND RULE 29.6 STATEMENT**

In addition to the parties named in the caption, the following parties were named as defendants in earlier iterations of the complaint: Bogush & Grady, LLP; Terence M. Bogush; Michael Cornelius; Lodewijk de Vink; Stephen Karasick; Anjan Mukherjee; Matt S. Pattullo; Brent D. Stiefel; and Todd Stiefel. Pursuant to this Court’s Rule 29.6, undersigned counsel state that Petitioner Stiefel Laboratories, Inc. is 100% owned, through several layers of wholly owned subsidiaries, by GlaxoSmithKline plc, a public limited company organized and existing under the laws of the United Kingdom. GlaxoSmithKline plc is publicly listed on the New York Stock Exchange and the London Stock Exchange, with the stock ticker symbol “GSK.”

TABLE OF CONTENTS

| | <i>Page</i> |
|--------------------------------------------------------------------------------------------------------------------------------------|-------------|
| QUESTION PRESENTED | i |
| PARTIES TO THE PROCEEDING AND RULE 29.6 STATEMENT | ii |
| TABLE OF CONTENTS | iii |
| TABLE OF APPENDICES | v |
| TABLE OF CITED AUTHORITIES | vi |
| PETITION FOR A WRIT OF CERTIORARI | 1 |
| OPINIONS BELOW | 1 |
| JURISDICTION | 1 |
| STATUTORY PROVISIONS INVOLVED | 1 |
| INTRODUCTION | 1 |
| STATEMENT | 3 |
| REASONS FOR GRANTING THE PETITION | 8 |
| I. THE CIRCUITS ARE DIVIDED ON THE EXISTENCE AND SCOPE OF A DUTY TO UPDATE PRIOR TRUTHFUL CORPORATE STATEMENTS | 10 |

Table of Contents

| | <i>Page</i> |
|----------------------------------------------------------------------------|-------------|
| II. THIS COURT'S REVIEW IS REQUIRED TO ESTABLISH A UNIFORM RULE | 17 |
| CONCLUSION | 20 |

TABLE OF APPENDICES

| | <i>Page</i> |
|-------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| APPENDIX A — OPINION OF THE UNITED STATES COURT OF APPEALS FOR THE ELEVENTH CIRCUIT, DATED JUNE 30, 2014 | 1a |
| APPENDIX B — FINAL JUDGMENT OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF FLORIDA, DATED JULY 9, 2012 | 30a |
| APPENDIX C — ORDER DENYING PETITION FOR REHEARING OF THE UNITED STATES COURT OF APPEALS FOR THE ELEVENTH CIRCUIT, FILED SEPTEMBER 8, 2014 | 32a |
| APPENDIX D — STATUTORY AND RULE PROVISIONS INVOLVED | 35a |

TABLE OF CITED AUTHORITIES

| | <i>Page</i> |
|--------------------------------------------------------------------------------------------|-------------|
| Cases | |
| <i>Backman v. Polaroid Corp.</i> , 910 F.2d 10 (1st Cir. 1990) | 10, 11, 18 |
| <i>Basic Inc. v. Levinson</i> , 485 U.S. 224 (1988). | 8, 9, 18 |
| <i>City of Edinburgh Council v. Pfizer, Inc.</i> , 754 F.3d 159 (3d Cir. 2014). | 17 |
| <i>Eisenstadt v. Centel Corp.</i> , 113 F.3d 738 (7th Cir. 1997). | 14 |
| <i>Gallagher v. Abbott Labs.</i> , 269 F.3d 806 (7th Cir. 2001). | 14 |
| <i>Glassman v. Computervision Corp.</i> , 90 F.3d 617 (1st Cir. 1996) | 11 |
| <i>Glazer v. Formica Corp.</i> , 964 F.2d 149 (2d Cir. 1992). | 10 |
| <i>Grassi v. Information Res., Inc.</i> , 63 F.3d 596 (7th Cir. 1995). | 14 |
| <i>Gross v. Summa Four, Inc.</i> , 93 F.3d 987 (1st Cir. 1996) | 11 |
| <i>Higginbotham v. Baxter Int’l Inc.</i> , 495 F.3d 753 (7th Cir. 2007). | 14, 15 |

Cited Authorities

| | <i>Page</i> |
|------------------------------------------------------------------------------------------------------------------------------------|-------------|
| <i>Hillson Partners Ltd. P'ship v. Adage, Inc.</i> , 42 F.3d 204 (4th Cir. 1994) | 15 |
| <i>In re Burlington Coat Factory Sec. Litig.</i> , 114 F.3d 1410 (3d Cir. 1997) | 15, 16, 17 |
| <i>In re Omnicare, Inc. Sec. Litig.</i> , 769 F.3d 455 (6th Cir. 2014) | 10 |
| <i>In re Time Warner, Inc. Sec. Litig.</i> , 9 F.3d 259 (2d Cir. 1993) | 11, 12, 13 |
| <i>Kowal v. Int'l Bus. Machs. Corp. (In re Int'l Bus. Machs. Corp. Sec. Litig.)</i> , 163 F.3d 102 (2d Cir. 1998) | 13 |
| <i>Matrixx Initiatives, Inc. v. Siracusano</i> , 563 U.S. ---, 131 S. Ct. 1309 (2011) | 9, 18 |
| <i>Minneapolis Firefighters' Relief Ass'n v. MEMC Elec. Materials, Inc.</i> , 641 F.3d 1023 (8th Cir. 2011) | 15, 18 |
| <i>Pommer v. Medtest Corp.</i> , 961 F.2d 620 (7th Cir. 1992) | 13 |
| <i>Roeder v. Alpha Indus., Inc.</i> , 814 F.2d 22 (1st Cir. 1987) | 10 |
| <i>Shaw v. Digital Equip. Corp.</i> , 82 F.3d 1194 (1st Cir. 1996) | 11 |

Cited Authorities

| | <i>Page</i> |
|-----------------------------------------------------------------------------------------|-------------|
| <i>Smith v. Duff & Phelps, Inc.</i> , 891 F.2d 1567 (11th Cir. 1990) | 8 |
| <i>Stransky v. Cummins Engine Co., Inc.</i> , 51 F.3d 1329 (7th Cir. 1995) | 13, 14, 15 |
| <i>United States v. Gordon</i> , 710 F.3d 1124 (10th Cir. 2013) | 10 |
| <i>United States v. Schiff</i> , 602 F.3d 152 (3d Cir. 2010) | 10, 17 |

Statutes and Other Authorities

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| 17 C.F.R. § 240.10b-5 | 1 |
| 15 U.S.C. § 78j(b) | 1, 2 |
| 15 U.S.C. § 78u-4(b)(2) | 11 |
| 28 U.S.C. § 1254(1) | 1 |
| Securities Exchange Act § 10b | 1, 2, 8, 9 |
| Securities Exchange Rule § 10b-5 | 1, 9, 13, 14, 18 |
| Donald C. Langefoort & G. Mitu Gulati, <i>The Muddled Duty to Disclose Under Rule 10B-5</i> , 57 Vand L. Rev. 1639, 1664 (2004) | 10 |

Cited Authorities

| | <i>Page</i> |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| Gregory S. Porter, <i>What Did You Know and When Did You Know It?: Public Company Disclosure and the Mythical Duties to Correct and Update</i> , 68 Fordham L. Rev. 2199, 2215 (2000) . . . | 18, 19, 20 |
| Harold S. Bloomenthal & Samuel Wolff, 10A Int'l Cap. Markets & Sec. Reg. § 15:23 (2014) | 9 |
| Sydney Ember, <i>Morning Agenda: Return of the Mega Merger</i> , N.Y. Times, Nov. 19, 2014, available at http://dealbook.nytimes.com/2014/11/18/morning-agenda-return-of-the-mega-merger/ . . . | 17 |

PETITION FOR A WRIT OF CERTIORARI

Petitioners Stiefel Laboratories, Inc. and Charles Stiefel respectfully petition for a writ of certiorari to review the judgment of the United States Court of Appeals for the Eleventh Circuit.

OPINIONS BELOW

The opinion of the United States Court of Appeals for the Eleventh Circuit (App. 1a-29a) is reported at 756 F.3d 1310. The Eleventh Circuit's order denying rehearing and rehearing *en banc* on September 8, 2014 (App. 32a-34a), is unreported. The district court's judgment (App. 30a-31a) is also unreported.

JURISDICTION

The Eleventh Circuit's opinion was filed on June 30, 2014. The court denied petitioners' Petition for Rehearing and/or Rehearing *En Banc* on September 8, 2014.

This Court's jurisdiction is invoked under 28 U.S.C. § 1254(1).

STATUTORY PROVISIONS INVOLVED

Section 10(b) of the Securities Exchange Act, 15 U.S.C. § 78j(b), and Securities Exchange Rule 10b-5, promulgated under 17 C.F.R. § 240.10b-5, are reproduced in the appendix to this petition. (App. 35a-37a).

INTRODUCTION

This petition requests the Court's guidance on an issue that has confounded the courts of appeals for more than twenty years: whether a corporation has a duty under Section 10(b) of the Securities Exchange

Act, 15 U.S.C. § 78j(b), to “update” a prior truthful statement.

The Seventh Circuit has flatly – and repeatedly – held that no such duty exists, a view that the Fourth and Eighth Circuits have approved. The Second and Third Circuits, on the other hand, have endorsed a closely cabined duty to update. The First Circuit, although identifying the possibility of a “duty to update” a prior correct statement, has only imposed a duty to correct a prior misleading statement.

Here, the Eleventh Circuit held that, because a jury could have found under Section 10(b) that the defendant company had a duty to update a prior truthful statement, in this case, involving the disclosure of preliminary or exploratory merger discussions, the defendant should be liable for securities fraud. This holding creates inter-circuit conflict on an important question of law.

Those prior decisions that have accepted the potential existence of a duty to update have attempted to limit or constrain the scope of any required disclosure. The courts have done so based on the common-sense understanding that a broadly applicable “update” duty would require a constant stream of corporate information to flow from senior management to the public, with predictably difficult consequences, and little corresponding benefit to investors.

The current conflict will create uncertainty for companies confronting the risk that disclosure may preclude or cripple both potential merger and other corporate opportunities, but also facing the risk that nondisclosure may subject a company to charges of securities fraud. This Court’s review is thus critical

to restore this important jurisprudence to a sensible and practical balance. The division among the circuits uniquely postures the Eleventh Circuit's decision for this Court's review.

STATEMENT

1. From 1986 through August 2008, Timothy Finnerty worked for Stiefel Laboratories, Inc. (SLI). (App. 4a). Until July 2009, SLI was a privately held pharmaceutical company. (App. 2a; R:552:17, 97). Along with 500-600 other SLI employees, Finnerty participated in SLI's Employee Stock Bonus Plan (the ESBP), which SLI had voluntarily funded with annual contributions of stock or cash since 1975. (R:471:1; R:552:93-95). The ESBP was governed by the rules and regulations applicable to employee stock ownership plans. Under the ESBP and the Employee Retirement Income Security Act (ERISA), eligible ESBP participants were entitled to demand a stock distribution from the ESBP and then to require SLI to purchase their shares at a price set annually by the ESBP's trustee, based upon an independent appraisal. (R:471:1-2, 5; R:552:94-97).

In August 2007, SLI announced that Blackstone Health Care Partners LLC (Blackstone) had agreed to invest \$500 million in SLI, an investment that represented a major change in SLI's corporate governance. (R:552:108-09; DX:32; PX:189; App. 3a, 11a). The announcement stated that, upon the impending closing of the investment, SLI "will continue to be a privately held company" and the Stiefel family will retain control, but warned that other options might be pursued:

There are currently no plans for [SLI] to become a publicly traded company.

Blackstone will have a defined exit arrangement with [SLI] at the end of eight years, at which point [SLI] may choose to buy back its shares or exercise other options, one of which might be an initial public offering. Senior management continues to evaluate all options when looking at the long-term financial needs of the company.

(App. 3a-4a; DX:32). Finnerty read that announcement. (R:552:45-46).

Finnerty had 28.22 shares of SLI common stock in his ESBP account in August 2008, when his employment was terminated as part of a company-wide reduction in force. (R:471:2; R:552:18-24, 118-20; App. 4a). Finnerty then went to work for an SLI competitor. (R:552:120-21).

On January 6, 2009, Finnerty elected irrevocably to sell (or “put”) his shares to SLI at the then-appraised value of \$16,469 per share. (App. 4a; R:471:2; PX:704). Finnerty made that election because he had decided “it was time to cash out,” after he received notice from SLI that the company intended to merge its 401(k) plan with the ESBP. (R:521-1:1-2; R:552:47-49; PX:109; App. 4a).

2. In November 2008, Sanofi-Aventis (Sanofi) had approached SLI to discuss a possible future business relationship. (R:552:133-34; R:553:66-73). On November 26, 2008, Charles Stiefel and his two sons, both SLI officers and directors, agreed to explore this unsolicited interest. (PX:301; App. 5a). On December 22, 2008, Charles Stiefel met for one hour with Sanofi’s top executive, but did not discuss either terms or price. (R:552:153; PX:123; App. 5a). SLI engaged an investment advisory firm to assist

with a sale exploration process on December 30, 2008. (PX:191; R:552:154; App. 5a). Sanofi entered a non-disclosure agreement with SLI on January 21, 2009, and GlaxoSmithKline plc (GSK) and three others entered into similar agreements, or expressed interest in SLI, in late January or early February 2009. (DX:45A; DX:45B; DX:45D; R:552:156-58; App. 5a). At the time Finnerty put his stock to SLI on January 6, 2009, there had been: (1) no SLI board meetings or board resolutions relating to a possible sale or merger; (2) no presentations made to potential strategic acquirers; (3) no receipt of any indications of value or price from a potential strategic acquirer; (4) no substantive talks or negotiations with any potential strategic acquirer; and (5) no due diligence.

On March 12, 2009, the sale exploration process was first addressed by the Board of Directors. (R:552:185-86; DX:164). Almost two weeks later, on March 24, 2009, SLI received its first indication of price and terms from two prospective strategic acquirers. (DX:168A; DX:168B; R:552:194).

SLI ultimately entered into a merger agreement with a subsidiary of GSK on April 20, 2009, pursuant to which GSK purchased SLI's stock for approximately \$3 billion, or approximately \$69,000 per share. (App. 6a; DX:46; DX:171; R:408:2; R:551:112; R:552:200). The merger closed in July 2009. (PX:339). Several ESBP participants, including Finnerty, thereafter sued SLI in a putative class action. (R:1; App. 6a). After the district court denied class certification and granted summary judgment for SLI on other plaintiffs' individual claims, the case came to trial on Finnerty's securities fraud claim. (R:257; R:384; R:390; R:495; App. 6a).

Finnerty's theory of recovery was that, when SLI first undertook to engage in "exploratory" or "speculative" discussions about merger options in late November 2008, its "failure to disclose the merger negotiations rendered ... misleading" SLI's prior statements about its privately held status, because SLI "no longer intended to remain private." (R:555:20-21, 34-35; R:562:17). Finnerty sought to recover – and was awarded – what he asserted was "the difference between what he should have gotten and what he got" for his shares, *i.e.*, \$1.5 million. (R:515; R:555:53-54; App. 7a).

3. On appeal, the Eleventh Circuit ruled that the jury could have found that SLI had a duty to disclose its willingness to consider a possible merger to Finnerty (who, by that time, was working for a competitor of SLI and thus had no legal obligation to maintain the confidentiality of any information disclosed to him). (App. 10a-17a; R:552:120-21). The court held that SLI's August 2007 statement that it "will continue to be privately held" could have had "a special significance" to Finnerty "because the statements were reinforced by the company's history and longstanding philosophy." (App. 11a). Despite how "[a]n investor who was unfamiliar with this history" would have construed SLI's (August 2007) statements, the panel ruled that Finnerty, who presented evidence that "generations of Stiefels express[ed] their commitment to keeping SLI under the family's control, could reasonably have understood the statements ... to be assurances that SLI remained unavailable for acquisition." (App. 11a).

Nor did the court believe that SLI's announcement about the Blackstone investment in

August 2007, while Finnerty was still employed by SLI, that its management team, going forward, would “continue [] to evaluate all options when looking at the long-term financial needs of the company,” was sufficient to put Finnerty on notice that SLI’s corporate philosophy had changed. (R:552:108-09; DX:32; PX:189; App. 12a-13a). The Eleventh Circuit acknowledged that “the phrase ‘evaluate all options’ can plausibly be construed” as an indication of SLI’s “willingness to entertain acquisition offers,” which “neutralized any misleading effects of its statements that SLI ‘will continue to be privately held.’” (App. 12a-13a). But the court nonetheless held a jury could have found that “nondisclosure of SLI’s interest in a merger with Sanofi-Aventis” could have “misled the investors who were also SLI employees into believing that the company remained unavailable for acquisition, when in fact it was in engaged in serious talks with a potential acquirer,” such that “nondisclosure rendered SLI’s ‘will continue to be privately held’ statements misleading or deceptive to the investors who were also SLI employees.” (App. 12a). According to the court, “a reasonable employee would have had no reason to think that the ‘evaluate all options’ language qualified or contradicted the [post-Blackstone] declaration that SLI ‘will continue to be privately held’” upon the closing the Blackstone investment. (App. 13a).

Based on this reasoning, the court held that the jury could have found that SLI had a “duty to update” its statement, but that SLI’s duty was limited to Finnerty only, despite the fact that hundreds of other ESBP participants were eligible to make benefit elections around the same time as

Finnerty. (App. 8a-14a). At the same time, the court recognized that it had “acknowledged ... that corporations may previously ‘have a justifiable reluctance’ to publicly disclose preliminary merger discussions because disclosure ‘could spark competition that might drive down bids, or could make potential bidders reluctant to make offers at all.’” (App. 15a n.6, quoting *Smith v. Duff & Phelps, Inc.*, 891 F.2d 1567, 1574 (11th Cir. 1990)). The court suggested that “SLI was under no obligation to disclose the existence or the status of its merger negotiations,” but could have merely said to Finnerty that “a sale of the company was under consideration.” (App. 15a).

Beyond that, the court refused to set forth any guidance for corporations and officers that maintain ESBPs or otherwise are obligated to purchase stock: “[W]hile we hold that SLI had a duty to disclose the fact that a sale was under active consideration, we leave open the issue of precisely when and to whom the requisite disclosure must be made.” (App. 15a n.5). The court also declined to “decide whether SLI had an immediate duty to update the public” about its preliminary discussions, holding that “SLI had a duty to update Finnerty at least before it repurchased shares of its own stock from him.” (App. 15a).

REASONS FOR GRANTING THE PETITION

In *Basic Inc. v. Levinson*, 485 U.S. 224 (1988), this Court’s touchstone decision on the materiality of a company’s merger negotiations or discussions, the Court carefully drew the line between the *materiality* element of securities fraud under Section 10(b) of the

Securities Exchange Act and Rule 10b-5, on the one hand, and the separate *duty-to-disclose* element:

[T]his case does not concern the *timing* of a disclosure; it concerns only its accuracy and completeness. We face here the narrow question whether information concerning the existence and status of preliminary merger discussions is significant to the reasonable investor's trading decision. Arguments based on the premise that some disclosure would be "premature" in a sense are more properly considered under rubric of an issuer's duty to disclose....

Basic, 485 U.S. at 235 (original emphasis) (footnote omitted). As the Court more recently has reaffirmed, "§ 10(b) and Rule 10b-5(b) do not create an affirmative duty to disclose any and all material information." *Matrixx Initiatives, Inc. v. Siracusano*, 563 U.S. ---, 131 S. Ct. 1309, 1321 (2011).

This is so, of course, because "[s]ilence, absent a duty to disclose, is not misleading under Rule 10b-5." *Basic*, 485 U.S. at 239 n.17; *accord Matrixx*, 131 S. Ct. at 1322. Indeed, the Securities Exchange Act "is not designed to produce timely corporate disclosure of material developments or even the reporting of all material developments." Harold S. Bloomenthal & Samuel Wolff, 10A Int'l Cap. Markets & Sec. Reg. § 15:23 (2014). A duty to disclose, as every circuit has held, has thus far been imposed only based on: (i) insider trading;¹ (ii) a statute or regulation requiring disclosure; or (iii) an "inaccurate,

¹ This case was not tried based on a theory of insider-trading, and the jury was not instructed on insider-trading liability. The Eleventh Circuit rested its disclosure duty solely upon SLI's purported duty to update Finnerty. (App. 14a-15a).

incomplete or misleading prior disclosure[].” *Backman v. Polaroid Corp.*, 910 F.2d 10, 12 (1st Cir. 1990) (*en banc*) (quoting *Roeder v. Alpha Indus., Inc.*, 814 F.2d 22, 27 (1st Cir. 1987)); *accord In re Omnicare, Inc. Sec. Litig.*, 769 F.3d 455, 471 (6th Cir. 2014); *United States v. Gordon*, 710 F.3d 1124, 1142 (10th Cir. 2013); *United States v. Schiff*, 602 F.3d 152, 162 (3d Cir. 2010); *Glazer v. Formica Corp.*, 964 F.2d 149, 157 (2d Cir. 1992).

The Eleventh Circuit held that a jury could have found a duty to disclose SLI’s preliminary merger discussions to Finnerty based on a “duty to update” Finnerty arising from a past, truthful statement before Finnerty irrevocably put his shares to SLI, pursuant to his rights under the ESBP. (App. 12-15). The duty-to-update theory has been described as “the most controversial ‘duty’ doctrine under Rule 10b-5,” Donald C. Langefoort & G. Mitu Gulati, *The Muddled Duty to Disclose Under Rule 10B-5*, 57 Vand L. Rev. 1639, 1664 (2004), and rightly so. The Eleventh Circuit’s decision here adds no clarity to that duty. Instead, it exacerbates a conflict among the circuits, which this Court should resolve to restore both uniformity and certainty to the rules by which businesses and the courts operate.

I. THE CIRCUITS ARE DIVIDED ON THE EXISTENCE AND SCOPE OF A DUTY TO UPDATE PRIOR TRUTHFUL CORPORATE STATEMENTS

The First Circuit initially gave voice to a possible “duty to update” theory, separate and apart from a duty to *correct* a prior misleading statement, in *Backman*:

We may agree that, in special circumstances, a statement, correct at the time, may have a

forward intent and connotation upon which parties may be expected to rely. If this is a clear meaning, and there is a change, correction, more exactly, per the disclosure, may be called for.

910 F.2d at 17. Because the court resolved the case on a duty-to-correct theory, however, it declined to address what it recognized as troubling questions as to limits on the duty to update, most particularly the “[f]ear that statements of historical fact might be claimed to fall within it,” which could “inhibit disclosures altogether.” *Id.*²

The Second Circuit, while thereafter “agree[ing] that a duty to update opinions and projections may arise if the original opinions or projections have become misleading as a result of intervening events,” distinguished between statements that “lack the sort of definite positive projections that might require later correction” and those that constitute such projections. *In re Time Warner, Inc. Sec. Litig.*, 9 F.3d 259, 267-68 (2d Cir. 1993).³ The Second Circuit

² The First Circuit has not since clarified the *Backman* formulation, except to reject attempts to invoke a duty to update for “cautiously optimistic comments that would not be actionable in the first instance.” *Shaw v. Digital Equip. Corp.*, 82 F.3d 1194, 1219 n.33 (1st Cir. 1996), *abrogated in part on other grounds* by 15 U.S.C. § 78u-4(b)(2); *see also* *Gross v. Summa Four, Inc.*, 93 F.3d 987, 995 (1st Cir. 1996), *abrogated in part on other grounds* by 15 U.S.C. § 78u-4(b)(2); *Glassman v. Computervision Corp.*, 90 F.3d 617, 635-36 (1st Cir. 1996). None of these decisions cited the *en banc* decision in *Backman* for this proposition, thus providing little guidance for how any recognition of a theoretical duty to update should be applied.

³ The court drew a distinction between two alleged non-disclosures: (i) the company’s “failure to disclose problems in the [company’s] strategic alliance negotiations”; and (ii) “failure
(continued . . .)

left it to a jury – or, if the historical facts are not in dispute, a district court on summary judgment – to determine the scope of the duty to update in any given case:

We do not hold that whenever a corporation speaks, it must disclose every piece of information in its possession that could affect the price of its stock. Rather, we hold that when a corporation is pursuing a specific business goal and announces that goal as well as an intended approach for reaching it, it may come under an obligation to disclose other approaches to reaching the goal when those approaches are under active and serious consideration. Whether consideration of the alternate approach constitutes material information, and whether nondisclosure of the alternate approach renders the original disclosure

(... continued)

to disclose the active consideration of an alternative method of raising capital.” *Id.* at 266. As to the first, the court ruled the statements “suggest[ed] only the hope of any company, embarking on talks with multiple partners, that the talks would go well,” and thus “did not become materially misleading when the talks did not proceed well.” *Id.* at 267. As to “the allegation of a failure to disclose the simultaneous consideration of [a] rights offering as an alternative method of raising capital,” the court held that “Time Warner’s public statements could have been understood by reasonable investors to mean that the company hoped to solve [its] *entire* debt problem through strategic alliances,” and, “[h]aving publicly hyped strategic alliances, Time Warner may have come under a duty to disclose facts that would place the statements concerning strategic alliances in a materially different light.” *Id.* at 267-68 (original emphasis).

misleading, remain questions for the trier of fact, and may be resolved by summary judgment when there is no disputed issue of material fact.

Id. at 268.⁴

The Seventh Circuit has entirely rejected this approach. Holding that Rule 10b-5 “implicitly precludes basing liability on circumstances that arise after the speaker makes the statement,” the court noted that it “has never embraced” a duty to update “and we decline to do so now.” *Stransky v. Cummins Engine Co., Inc.*, 51 F.3d 1329, 1332 (7th Cir. 1995). The court explained that “[t]he securities laws typically do not act as a Monday Morning Quarterback”, but rather “approach matters from an *ex ante* prospective: just as a statement true when made does not become fraudulent because things unexpectedly go wrong, so a statement materially false when made does not become acceptable because it happens to come true.” *Id.* (quoting *Pommer v. Medtest Corp.*, 961 F.2d 620, 623 (7th Cir. 1992)).⁵

⁴ The Second Circuit has reaffirmed *Time Warner*, holding that “[a] duty to update may exist when a statement, reasonable at the time it is made, becomes misleading because of a subsequent event.” *Kowal v. Int’l Bus. Machs. Corp. (In re Int’l Bus. Machs. Corp. Sec. Litig.)*, 163 F.3d 102, 110 (2d Cir. 1998). But the court declined to apply that duty to “vague expressions of opinion which are not sufficiently concrete, specific or material to impose a duty to update,” and that were both true when spoken and “accompanied by qualifying language indicating that the speaker was only referring to the short term.” *Id.*

⁵ The court, however, endorsed the duty to *correct*, which “applies when a company makes a historical statement that, at the time made, the company believed to be true, but as revealed
(continued . . .)

Since *Stransky*, the Seventh Circuit has repeatedly rejected the notion that Section 10(b) imposes a duty to update. See, e.g., *Higginbotham v. Baxter Int'l Inc.*, 495 F.3d 753, 760-61 (7th Cir. 2007); *Gallagher v. Abbott Labs.*, 269 F.3d 806, 809-10 (7th Cir. 2001); *Eisenstadt v. Centel Corp.*, 113 F.3d 738, 745-46 (7th Cir. 1997); *Grassi v. Information Res., Inc.*, 63 F.3d 596, 599-600 (7th Cir. 1995). In *Gallagher*, the Seventh Circuit reviewed unadopted proposals for “continuous disclosure” that have been offered over the years, but emphasized that “[w]e do not have a system of continuous disclosure” under current statutes and regulations, but rather “firms are entitled to keep silent (about good news as well as bad news) unless positive law creates a duty to disclose.” 269 F.3d at 808-09. “Whatever may be said for and against these proposals, they must be understood as projects for legislation (and to a limited extent for the use of the SEC’s rulemaking powers); judges have no authority to scoop the political branches and adopt continuous disclosure under the banner of Rule 10b-5.” *Id.* at 809.

And, as the court emphasized: “*Especially* not under that banner, for Rule 10b-5 condemns only fraud, and a corporation does not commit fraud by standing on its rights under a periodic-disclosure system.” *Id.* at 809-10 (original emphasis). In *Higginbotham*, the court continued to distinguish “between a duty to update disclosures by adding the latest information and a duty to correct disclosures *false when made*.” 495 F.3d at 760 (emphasis added).

(... continued)

by subsequently discovered information actually was not.” *Id.* at 1331.

In explicating its adherence to *Stransky*, the court stated:

[W]hat rule of law requires 10-Q reports to be updated on any cycle other than quarterly? That's what the "Q" means. Firms regularly learn financial information between quarterly reports, and they keep it under their hats until the time arrives for disclosure. Silence is not "fraud" without a duty to disclose. The securities laws create a system of periodic rather than continual disclosures.

Higginbotham, 495 F.3d at 760 (citations omitted).

The Eighth Circuit has adopted the Seventh Circuit's rule, "declin[ing] to recognize a new cause of action absent extraordinary circumstances," because "[t]o do so could encourage companies to disclose as little as possible." *Minneapolis Firefighters' Relief Ass'n v. MEMC Elec. Materials, Inc.*, 641 F.3d 1023, 1028-29 (8th Cir. 2011). The Fourth Circuit, although not addressing the issue comprehensively, seems to have aligned itself with the Seventh Circuit's view. *Hillson Partners Ltd. P'ship v. Adage, Inc.*, 42 F.3d 204, 219 (4th Cir. 1994).

The Third Circuit reviewed the then-extant duty-to-update landscape in 1997, and took a different approach from that of the Seventh Circuit, endorsing a limited "duty to update a forward-looking statement," applicable only when "the projection contained an implicit factual representation that remained 'alive' in the minds of investors as a continuing representation." *In re Burlington Coat Factory Sec. Litig.*, 114 F.3d 1410, 1432 (3d Cir. 1997). The court declined to apply that duty to "an ordinary earnings projection," because

such a projection does not “contain[] an implicit representation on the part of the company that it will update the investing public with all material information that relates to the forecast.” *Id.* at 1433. To the contrary, “ordinary, run-of-the-mill forecasts contain no more than the implicit representation that the forecasts were made reasonably and in good faith,” and disclosure of such a forecast “does not contain the implication that the forecast will continue to hold good even as circumstances change.” *Id.* On the other hand:

Where the initial disclosure relates to the announcement of a fundamental change in the course the company is likely to take, there may be room to read in an implicit representation by the company that it will update the public with news of any radical change in the company’s plans – *e.g.*, news that [a] merger is no longer likely to take place. But finding a duty to update a disclosure of a takeover threat is a far cry from finding a duty to update a simple earnings forecast which, if anything, contains a clear implication that circumstances underlying it are likely to change.

Id. at 1433-44 (citation and footnote omitted).

The court “emphasize[d] that we are *not* saying that once a fundamental change is announced the company faces a duty continuously to update the public with all material information relating to that change.” *Id.* at 1434 n.20 (original emphasis). Rather, “the duty to update, to the extent that it might exist, would be a narrow one to update the public as to *extreme* changes in the company’s originally expressed expectation of an event such as

a takeover, merger, or liquidation.” *Id.* (original emphasis).

The Third Circuit has since stressed the strictly limited duty that it recognized in *Burlington* is “a narrow duty because of the potential to create a sweeping continuing obligation for corporations when they disclose information.” *Schiff*, 603 F.3d at 170. “[T]he duty has only been plausible in cases where the initial statement concerns ‘*fundamental*[] change[s] in the nature of the company – such as a merger, liquidation, or takeover attempt – and when the subsequent events produce an ‘*extreme*’ or ‘radical change’ in the continuing validity of that statement.” *Id.* (original emphasis) (quoting *Burlington*, 114 F.3d at 1433-34 & n.20); accord *City of Edinburgh Council v. Pfizer, Inc.*, 754 F.3d 159, 176 (3d Cir. 2014).

II. THIS COURT’S REVIEW IS REQUIRED TO ESTABLISH A UNIFORM RULE

This case shows the need for this Court’s guidance and for a uniform rule on which companies, shareholders, and courts can rely. That need is all the more pressing as improving economic conditions foster a new spate of corporate mergers, stock buybacks, and the like.⁶ Both those involved in corporate dealmaking and those who must contend with the unintended consequences of such dealmaking are entitled to know the disclosure rules – clearly and in advance.

⁶ See Sydney Ember, *Morning Agenda: Return of the Mega Merger*, N.Y. Times, Nov. 19, 2014, available at <http://dealbook.nytimes.com/2014/11/18/morning-agenda-return-of-the-mega-merger/> (last visited Dec. 4, 2014).

The Court has not yet addressed whether any duty to update exists, and, if it does, when and what disclosures must be made. In *Matrixx*, however, the Court, after reaffirming the rule that “[s]ilence, absent a duty to disclose, is not misleading under Rule 10b-5,” 131 S. Ct. at 1321 (quoting *Basic*, 485 U.S. at 239 n.17), commented: “Even with respect to information that a reasonable investor might consider material, companies can control what they have to disclose under these provisions by controlling what they say to the market.” *Id.* at 1321-22. The Eighth Circuit, in its decision adopting the Seventh Circuit’s precedent, suggested that this dictum might provide “the best support” for a duty-to-update theory. *Minneapolis Firefighters’ Relief*, 641 F.3d at 1028-29. That view speaks further to the need for this Court’s review.

And the protean nature of the Eleventh Circuit’s purported duty to update only sharpens the need for a uniform rule. In a critique of the *Backman* formulation that could have been written in response to the Eleventh Circuit’s decision, one commentator has suggested that the end result would be that “every material development would allow a plaintiff to point to a ‘misleading’ prior statement.” Gregory S. Porter, *What Did You Know and When Did You Know It?: Public Company Disclosure and the Mythical Duties to Correct and Update*, 68 Fordham L. Rev. 2199, 2215 (2000).⁷ Such a rule “would

⁷ As the author explains, if a company had a “good year,” the results of which are reflected in its Form 10-K annual report, and then “hits hard times” in the first quarter of the following year, before its first quarter 10-Q filing is due, “[t]he fact that the company is now losing money is undoubtedly material,” but that, “[t]o claim that the company has no duty to disclose all
(continued . . .)

impose an even higher liability cost than would a continuous disclosure system that only required disclosure of factual information” by “requir[ing] a company to update its prior statements any time additional information cast doubt on a prior prediction or, if the company would generate a new prediction, it would cause the corporation to formulate a different prediction.” *Id.* at 2234. “In a continuous disclosure system, the number of difficult disclosure decisions is multiplied exponentially, with each decision subject to being second guessed in subsequent litigation.” *Id.* at 2235.⁸ Given the

(... continued)

material information and then to allow an argument that the losses ... make an earlier true statement ‘misleading’ thereby requiring additional disclosure, is nonsensical.” *Id.*

⁸ The author suggests that distinguishing between forward-looking statements and “historical” statements when imposing a duty to update will lead to “anomalous outcome[s].” *Id.* at 2241. He posits two companies, the Alpha Company and the Beta Company, which undertake negotiations for a merger after making two different statements that were believed to be true when made. *Id.* at 2241-42. The Alpha Company stated that it was “not involved in any of the negotiations regarding a material acquisition,” and the Beta Company stated that it had no “plan to make any material acquisitions this year.” *Id.* at 2241. Thus, when the companies began negotiations, “Alpha Company would have no duty to provide any additional information regarding its acquisition plans,” while Beta Company, having made a statement with “a forward-looking component, ... would now be required to update its earlier statement.” *Id.* at 2242. Beta Company would have to make that disclosure “despite the fact that no acquisition had been consummated and despite the significant possibility that no acquisition will result from the ... negotiations.” *Id.* The author rightly suggests that “[n]o justification exists for holding Beta Company liable for not disclosing unquestionable material

(continued ...)

conflict among the circuits as to the existence and contours of a duty to update past, truthful statements, this Court's guidance is both necessary and timely.

CONCLUSION

For the reasons set forth above, the petition for a writ of certiorari should be granted.

Respectfully submitted,

Todd D. Wozniak
Greenberg Traurig, LLP
Terminus 200
3333 Piedmont Road
NE, Suite 2500
Atlanta, Georgia 30305
Tel: 678.553.2100

Elliot H. Scherker
Counsel of Record
Hilarie Bass
David A. Coulson
Brigid F. Cech Samole
Greenberg Traurig, P.A.
333 S.E. Second Avenue
Suite 4400
Miami, Florida 33131
Tel: 305.579.0579
scherkere@gtlaw.com

Counsel for Petitioners

December 5, 2014

(... continued)

information when Alpha Company would not incur liability for withholding the same information." *Id.*

APPENDIX

1a

**APPENDIX A — OPINION OF THE UNITED
STATES COURT OF APPEALS FOR THE
ELEVENTH CIRCUIT, DATED JUNE 30, 2014**

UNITED STATES COURT OF APPEALS
FOR THE ELEVENTH CIRCUIT

No. 12-13947, No. 12-15060, No. 12-15642

TIMOTHY FINNERTY,

Plaintiff-Appellee,

v.

STIEFEL LABORATORIES, INC., a Delaware
Corporation, CHARLES W. STIEFEL,

Defendants-Appellants.

June 30, 2014, Decided

JUDGES: Before ANDERSON, Circuit Judge, and
MOODY* and SCHLESINGER,** District Judges.

OPINION BY: ANDERSON

OPINION

* Honorable James S. Moody, Jr., United States District
Judge for the Middle District of Florida, sitting by designation.

** Honorable Harvey E. Schlesinger, United States District
Judge for the Middle District of Florida, sitting by designation.

Appendix A

ANDERSON, Circuit Judge:

Plaintiff Timothy Finnerty filed this lawsuit against Stiefel Laboratories, Inc. (“SLI”) and its chief executive officer, Charles Stiefel (hereinafter jointly referred to as “SLI”), alleging violations of § 10(b) of the Securities Exchange Act of 1934 and accompanying Rule 10b-5. The allegation is that SLI withheld material information about preliminary merger negotiations that it was obliged to disclose. The case was tried before a jury which returned a verdict for Finnerty. The district court subsequently denied SLI’s renewed motion for judgment as a matter of law and alternative motion for a new trial. SLI appeals from that denial, arguing principally that it had no duty to disclose the merger negotiations, that the negotiations were immaterial, and that the district court erroneously refused to give a request to charge to the jury. For the reasons that follow, we affirm.

I. Background.¹

A. The Blackstone investment.

SLI was a privately-held pharmaceutical company controlled by the Stiefel family from its founding in 1847 until 2009, when it merged with GlaxoSmithKline (“GSK”). SLI took great pride in its privately-held status; the Stiefel family brought up this fact at nearly every

1. In accordance with our standard of review for renewed judgment as a matter of law, we present the facts in the light most favorable to Finnerty. *See SEC v. Ginsburg*, 362 F.3d 1292, 1296 (11th Cir. 2004).

Appendix A

company meeting and impressed upon employees their commitment to keeping SLI under the family's control.

In August 2007, SLI announced a \$500 million minority investment by The Blackstone Group ("Blackstone"). Under the terms of the investment, Blackstone purchased preferred shares at approximately \$60,000 per share. Additionally, in connection with the investment, Blackstone acquired the right to name one member of SLI's board of directors. Sometime in 2008, Blackstone named Anjan Mukherjee, a managing director at Blackstone, to SLI's board.

Anticipating the speculation that might result from Blackstone's investment, on August 9, 2007, SLI issued a press release that stated: "[SLI] . . . will continue to be privately held, and the Stiefel family will retain control and continue to hold a majority-share ownership of the company." That same day, Charles Stiefel sent an e-mail to SLI employees assuring them that "[SLI] will continue to be a privately held company operating under my direction as Chairman, Chief Executive Officer, and President." A "Frequently Asked Questions" document attached to the e-mail further informed employees:

Will [SLI] be going public?

There are currently no plans for [SLI] to become a publicly traded company. Blackstone will have a defined exit arrangement with [SLI] at the end of eight years, at which point [SLI] may choose to buy back its shares or exercise

Appendix A

other options, one of which might be an initial public offering. Senior management continues to evaluate all options when looking at the long-term financial needs of the company.

B. Finnerty’s “put” election.

Finnerty worked as a sales representative for SLI from 1986 until he was terminated on August 29, 2008, along with numerous others in a reduction of force. As an employee, Finnerty participated in SLI’s Employee Stock Bonus Plan (“ESBP”). Upon termination of employment, ESBP participants became entitled to a distribution of the vested benefits in their accounts paid in the form of SLI stock. Participants also received a “put” option on the distributed stock, which allowed them to require SLI to buy back the stock at a fair market value during a certain window of time.

Although Finnerty was eligible for his vested ESBP benefits after his termination, he initially elected to defer the distribution. But in November 2008, Finnerty received a letter from SLI announcing major changes to the ESBP. Shortly thereafter, Finnerty received another letter reminding him of the opportunity to take a distribution and providing him with the necessary paperwork. Concerned about the impending changes, on January 6, 2009, Finnerty executed a form irrevocably electing to receive his distribution of SLI stock and to “put” the stock to SLI at the then-effective fair market value of \$16,469 per share. SLI completed this transaction on February 13, 2009.

*Appendix A***C. The sale of SLI.**

Unknown to Finnerty, the Stiefel family had been exploring the possibility of selling SLI since November of 2008. Earlier that month, Mukherjee learned that the pharmaceutical giant Sanofi-Aventis was interested in an acquisition. Mukherjee advised the Stiefels that they should “either sell [SLI] right now or wait five years,” and he estimated that the acquisition price could be as high as “3-5 times sales,” with the price that Blackstone paid (\$60,000 per share) as the floor. On November 26, 2008, Charles Stiefel met with his sons and they decided to “move on” the sale.

On December 8, 2008, a team from Blackstone Advisory Services, an affiliate of Blackstone, presented to the Stiefels a marketing strategy and timeline for pursuing a sale, including a list of potential acquirers and a valuation analysis. The analysis suggested that the potential acquisition price could be in the range of \$2.25 to \$4 billion (around 2.5 to 4.5 times revenue). Later that month, Charles Stiefel met with the chief executive officer of Sanofi-Aventis to discuss how the two companies could operate together. No discussion of prices or terms took place at this meeting. Thereafter, around December 30, 2008, SLI hired Blackstone Advisory Services to advise on a potential sale.

In January 2009, SLI executed a confidentiality agreement with Sanofi-Aventis and contacted several other pharmaceutical companies to gauge their interest. Eventually, two companies—Sanofi-Aventis and GSK—

Appendix A

submitted non-binding bids for SLI. On April 20, 2009, SLI and GSK agreed to a transaction in which holders of SLI stock received approximately \$68,515.29 per share, with the possibility of another \$7,186.91 per share if certain performance conditions were met—more than four times the value received by Finnerty when he exercised his “put” option.

D. District court proceedings.

Finnerty brought suit against SLI on January 14, 2011, alleging violations of the Employee Retirement Income Security Act (“ERISA”) and § 10(b) of the Securities Exchange Act of 1934.² The securities fraud count was tried in May of 2012 on the theory that SLI had a duty to disclose to Finnerty information relating to its merger negotiations with Sanofi-Aventis but failed to do so.

At trial, the district court allowed Finnerty to elicit testimony that SLI had on occasion suspended the distribution of benefits from the ESBP (*i.e.*, imposed a “blackout”). SLI argued that this testimony misled jurors into believing that it could have refused to honor Finnerty’s “put” election and thus prejudiced its defense on the element of scienter. SLI sought to refute by

2. This lawsuit was originally brought as a class action. The district court denied class certification on July 21, 2011, and we subsequently denied the plaintiffs’ petition for a review of the order. The district court thereafter granted summary judgment against two of the three named plaintiffs, leaving only Finnerty’s claims. Finnerty had named other SLI executives and directors as defendants, but those individuals are not a part of this appeal.

Appendix A

testimony about its legal obligations under the terms of the ESBP and applicable federal law, but the district court excluded the testimony as impermissible legal opinion. However, SLI did introduce other testimony to the effect that it could not have imposed a “blackout” because it did not have time for the required thirty days’ notice and because it believed it could not disclose the reasons for the “blackout.” SLI also requested a jury instruction on its legal obligations—“With certain limited exceptions not applicable to this case, under federal law and the terms of the ESBP, [SLI] was required to purchase [Finnerty’s] shares of stock from him as soon as he exercised his irrevocable put right on January 6, 2009”—which the district court denied.

The jury returned a verdict in favor of Finnerty and awarded him compensatory damages of \$1,502,484.90. The district court subsequently denied SLI’s renewed motion for judgment as a matter of law and alternative motion for a new trial. This timely appeal followed.

II. Discussion.**A. Judgment as a matter of law.**

SLI argues that the district court erred in denying his motion for judgment as a matter of law. We review *de novo* the district court’s decision on this question. *Myers v. TooJay’s Mgmt. Corp.*, 640 F.3d 1278, 1287 (11th Cir. 2011). Our task is to consider whether the evidence, viewed in the light most favorable to Finnerty, is legally sufficient to support the verdict in his favor. *See id.* Only

Appendix A

if no reasonable jury could have found for Finnerty will we reverse. *See id.*

1. *Sufficiency of evidence of actionable omission.*

To succeed on a § 10(b) securities fraud claim, “a plaintiff must establish (1) a false statement or omission of material fact (2) made with scienter (3) upon which the plaintiff justifiably relied (4) that proximately caused the plaintiff’s injury.” *Robbins v. Koger Props., Inc.*, 116 F.3d 1441, 1447 (11th Cir. 1997). “[A] defendant’s omission to state a material fact is proscribed only when the defendant has a duty to disclose.” *Rudolph v. Arthur Andersen & Co.*, 800 F.2d 1040, 1043 (11th Cir. 1986). We have held that a duty to disclose may arise from a defendant’s previous decision to speak voluntarily. *See id.* Specifically, a duty exists to update prior statements if the statements were true when made, but misleading or deceptive if left unrevised. *See id.*

There is, of course, no obligation to update a prior statement about a historical fact. *See Stransky v. Cummins Engine Co.*, 51 F.3d 1329, 1332 n.3 (7th Cir. 1995) (“[T]hat circumstances subsequently change cannot render an historical statement false or misleading.”). The duty attaches only to forward-looking statements—statements that contain “an implicit factual representation that remain[s] ‘alive’ in the minds of investors as a continuing representation.” *In re Burlington Coat Factory Sec. Litig.*, 114 F.3d 1410, 1432 (3d Cir. 1997). Determining if such an implicit representation was present and whether

Appendix A

the representation subsequently became misleading involves an assessment of “the meaning of the statement to the reasonable investor and its relationship to truth.” *FindWhat Investor Grp. v. FindWhat.com*, 658 F.3d 1282, 1305 (11th Cir. 2011) (internal quotation marks omitted); *cf. Burlington*, 114 F.3d at 1432 (stating that determining whether a disclosure contains an implicit continuing representation “is a function of what a reasonable investor expects”); *San Leandro Emergency Med. Grp. Profit Sharing Plan v. Philip Morris Cos.*, 75 F.3d 801, 810 (2d Cir. 1996) (concluding that a prior statement did not give rise to a duty to update because the statement could not have “led any reasonable investor to conclude” that the company had made a commitment). Whether a company came under an obligation to revise a past disclosure is normally an issue for the finder of fact. *See In re Time Warner Inc. Sec. Litig.*, 9 F.3d 259, 268 (2d Cir. 1993) (“[W]hether nondisclosure . . . renders the original disclosure misleading[] remain[s a] question[] for the trier of fact”); *Clay v. Riverwood Int’l Corp.*, 157 F.3d 1259, 1268-69 (11th Cir. 1998) (concluding that “no reasonable jury could find” that revision was necessary to prevent an “extremely non-committal” disclosure from being misleading), *vacated in part on other grounds*, 176 F.3d 1381 (11th Cir. 1999).

In this case, SLI denies that it had a duty to disclose the preliminary merger negotiations with Sanofi-Aventis. Conversely, Finnerty argues that SLI’s August 2007 statements that it “will continue to be privately held, and the Stiefel family will retain control and continue to hold a majority-share ownership of the company” gave rise to a

Appendix A

duty to update when SLI considered itself to be a serious acquisition target. The jury, by its verdict, decided this issue in favor of Finnerty. We conclude that the evidence in the record is sufficient to support this determination.

The evidence at trial showed that SLI executives took great pride in the fact that the company had been privately held and controlled by the Stiefel family throughout its 162-year existence. Finnerty testified that the company's privately-held status "was brought up in virtually every meeting." A former member of SLI's board of directors similarly explained that it was "always the philosophy of the [Stiefel] family and the company" that SLI would remain privately owned. Another former SLI employee stated that the Stiefel family gave employees a "very clear understanding" that the family had "no plans of selling the company or going public." The employee specifically recounted a meeting that took place shortly before the merger with GSK was announced, at which a member of the Stiefel family told employees that SLI "was 160 years in the family" and there were no plans "to change that."³

3. Finnerty was not present at this meeting and so could not have relied on this statement. Otherwise, the statement might be actionable as an affirmative misrepresentation because SLI was actively engaged in preliminary merger discussions with Sanofi-Aventis at the time the statement was made. *Cf. FindWhat Investor Grp. v. FindWhat.com*, 658 F.3d 1282, 1298 (11th Cir. 2011) (holding that a statement is actionable when it could "mislead a reasonable investor into believing" an untrue fact). On the facts of this case, the statement is not evidence of a material misrepresentation on which Finnerty relied, but it is nonetheless evidence from which a jury could infer SLI's history of telling its employees that it was not available for acquisition.

Appendix A

This context is significant. The jury could have reasonably concluded that the investors who were also SLI employees attached a special significance to the statements that SLI “will continue to be privately held” because the statements were reinforced by the company’s history and longstanding philosophy. An investor who was unfamiliar with this history might have viewed the statements as too vague to be consequential; there was, after all, no indication of whether SLI intended to be privately held “for any given amount of time or even if business circumstances dictate to the contrary.” *Jackvony v. RIHT Fin. Corp.*, 873 F.2d 411, 417 (1st Cir. 1989) (concluding that an open-ended promise to operate target entity as an independent subsidiary is not inconsistent with decision to merge target entity into the parent company two years later). But SLI employees, who had heard generations of Stiefels express their commitment to keeping SLI under the family’s control, could reasonably have understood the “will continue to be privately held” statements to be assurances that SLI remained unavailable for acquisition even after Blackstone’s investment. *Cf. Philip Morris*, 75 F.3d at 810 (determining that a “hyped” plan could induce reasonable expectations among investors, but a “single, vague statement” could not).

The jury could have further inferred that SLI considered itself to be a serious acquisition target by the time it engaged Blackstone Advisory Services to advise on a potential sale. Retaining an investment bank, after corporate executives had met and begun to negotiate, “arguably demonstrate[s]” that a company’s intention to merge “has moved beyond its incipient stages and

Appendix A

ripened into purposeful action.” *Castellano v. Young & Rubicam, Inc.*, 257 F.3d 171, 180, 182 (2d Cir. 2001). The jury could have found that nondisclosure of SLI’s interest in a merger with Sanofi-Aventis misled the investors who were also SLI employees into believing that the company remained unavailable for acquisition, when in fact it was engaged in serious talks with a potential acquirer. In other words, the jury could have reasonably concluded that nondisclosure rendered SLI’s “will continue to be privately held” statements misleading or deceptive to the investors who were also SLI employees, thus giving rise to a duty to update.

SLI relies heavily on another part of the statements made to employees in August 2007—the Frequently Asked Questions document. In response to the hypothetical question “Will [SLI] be going public?”, the document answered:

There are currently no plans for [SLI] to become a publicly traded company. Blackstone will have a defined exit arrangement with [SLI] at the end of eight years, at which point [SLI] may choose to buy back its shares or exercise other options, one of which might be an initial public offering. Senior management continues to evaluate all options when looking at the long-term financial needs of the company.

Resting on the “evaluate all options” language, SLI contends that it had indicated its willingness to entertain acquisition offers and thereby neutralized any misleading

Appendix A

effects of its statements that SLI “will continue to be privately held.”

We do not dispute that the phrase “evaluate all options” can plausibly be construed in the manner that SLI urges. But we think other interpretations are equally tenable. For instance, the term “options” could refer back to the preceding sentence: “Blackstone will have a defined exit arrangement with [SLI] at the end of eight years, at which point [SLI] may choose to buy back its shares or exercise other options” Such a reading would have created the understanding among employees that SLI had not decided on an exit arrangement with Blackstone and was considering all possible alternatives. Because the exit would not take place for another eight years, a reasonable employee would have had no reason to think that the “evaluate all options” language qualified or contradicted the declarations that SLI “will continue to be privately held.” It was up to the jury to choose among these competing, permissible interpretations of the evidence. *See SEC v. Ginsburg*, 362 F.3d 1292, 1301 (11th Cir. 2004). Accordingly, we decline to disturb the verdict on this ground.⁴

4. The jury in this case entered a general verdict. As a result, because we conclude that the “will continue to be privately held” statements gave rise to a duty to update when SLI considered itself to be a serious acquisition target, we need not address Finnerty’s other theories of non-disclosure. *See Maiz v. Virani*, 253 F.3d 641, 672-73 (11th Cir. 2001) (endorsing the argument that “when reviewing a decision on a motion for judgment as a matter of law in a civil case, if any one basis for the verdict is valid, the judgment must be affirmed”).

Appendix A

It is important to appreciate the limits of our decision. We hold only that SLI had a duty to disclose facts that were necessary to make its “will continue to be privately held” statements not misleading. In other words, SLI was under no obligation to disclose the existence or the status of its merger negotiations with Sanofi-Aventis; it could have merely said that a sale of the company was under consideration.

Further, we do not decide whether SLI had an immediate duty to update the public when the negotiations with Sanofi-Aventis became serious. Rather, we hold that SLI had a duty to update Finnerty at least before it repurchased shares of its own stock from him.⁵ We think it may well be desirable to entrust the timing of disclosures to the business judgment of corporate officers where, as here, a duty to update exists but silence would yield benefits for investors as a group, so long as the company and its insiders abstain from trading in the company’s securities during this period of nondisclosure.⁶

5. In other words, while we hold that SLI had a duty to disclose the fact that a sale was under active consideration, we leave open the issue of precisely when and to whom the requisite disclosure must be made. Although there may be no practical difference in this case, we emphasize that we do not answer the question of whether SLI is a “close corporation” with a fiduciary duty to disclose material facts before trading in its own stock. *See Jordan v. Duff & Phelps, Inc.*, 815 F.2d 429, 435 (7th Cir. 1987); *Castellano v. Young & Rubicam, Inc.*, 257 F.3d 171, 179 (2d Cir. 2001).

6. We recognize that the Supreme Court in *Basic Inc. v. Levinson* expressed some doubt as to “whether secrecy”

Appendix A

Cf. Weiner v. Quaker Oats Co., 129 F.3d 310, 316 (3d Cir. 1997) (“Whether an amendment [updating prior speech] is sufficiently prompt is a question that must be determined in each case based upon the particular facts and circumstances.” (internal quotation marks omitted)); *SEC v. Tex. Gulf Sulphur Co.*, 401 F.2d 833, 850 n.12 (2d Cir. 1968) (“[W]here a corporate purpose is thus served by withholding the news of a material fact, those persons who are thus quite properly true to their corporate trust must not during the period of non-disclosure deal personally in the corporation’s securities . . .”). “Rule 10b-5 is about fraud, after all, and it is not fraudulent to conduct business in a way that makes investors better off.” *Basic Inc. v. Levinson*, 485 U.S. 224, 235 n.11, 108 S. Ct. 978, 985 n.11, 99 L. Ed. 2d 194 (1988) (emphasis omitted) (quoting *Flamm v. Eberstadt*, 814 F.2d 1169, 1177 (7th Cir. 1987)). But secrecy ceases to be in the investors’ interests when corporate insiders exploit the non-public information in their possession and engage in self-dealing. *Cf. United States v. O’Hagan*, 521 U.S. 642, 658, 117 S. Ct. 2199, 2210, 138 L. Ed. 2d 724 (1997) (“[T]rading on misappropriated [non-public] information ‘undermines the integrity of, and investor confidence in, the securities markets’” (quoting 45 Fed. Reg. 60,412 (September 12, 1980))). It makes

in preliminary merger discussions “necessarily maximizes shareholder wealth.” 485 U.S. 224, 235, 108 S. Ct. 978, 985, 99 L. Ed. 2d 194 (1988). Our Circuit has, however, acknowledged post-*Basic* that corporations may “have a justifiable reluctance” to publicly disclose preliminary merger discussions because disclosure “could spark competition that might drive down bids, or could make potential bidders reluctant to make offers at all.” *Smith v. Duff & Phelps, Inc.*, 891 F.2d 1567, 1574 (11th Cir. 1990).

Appendix A

scant sense to allow corporate officers who are privy to inside information to take unfair advantage of “outside” stockholders by causing the corporation to buy and sell shares at favorable prices so as to increase the value of the officers’ own equity. *See Smith v. Duff & Phelps, Inc.*, 891 F.2d 1567, 1574 (11th Cir. 1990) (warning that a company’s reluctance to disclose merger information to potential retirees may be motivated by “its fear that if the retirees knew of the possible merger, they would wait to retire until they could get the largest return, thus depriving the majority shareholders of larger profits”).

We need not decide here whether SLI could have postponed the duty to update their prior statements by abstaining from trading in the company’s securities because that is not the case before us. It is undisputed that SLI bought back shares of its own stock from Finnerty without first informing him that a sale of the company was under serious and active consideration. SLI argues that it was required by federal law to buy back the shares, even while in possession of undisclosed material information, because the securities were distributed pursuant to a stock bonus plan. This issue is explored below in Part II.B, *infra*. Furthermore, even if federal law does foreclose the option of abstention, it would not affect our disposition. A corporation that is unable to lawfully postpone its duty to disclose is not absolved of that duty. The Supreme Court has made clear that it is not the role of courts to interfere with the “philosophy of full disclosure” embodied in the securities laws. *Basic*, 485 U.S. at 230, 108 S. Ct. at 983 (quoting *Santa Fe Indus., Inc. v. Green*, 430 U.S. 462, 477, 97 S. Ct. 1292, 1303, 51 L. Ed. 2d 480 (1977)).

Appendix A

“[C]reating an exception to a regulatory scheme founded on a prodisclosure legislative philosophy, because complying with the regulation might be ‘bad for business,’ is a role for Congress, not this Court.” *Id.* at 239 n.17, 108 S. Ct. at 987 n.17.⁷

2. *Sufficiency of evidence that the omitted information was material.*

SLI also argues that Finnerty did not provide sufficient evidence to permit a reasonable jury to find that its merger talks with Sanofi-Aventis were material as required by Rule 10-b5. For an omission to be material, “there must be a substantial likelihood that the disclosure of the omitted fact would have been viewed by the reasonable investor as having significantly altered the ‘total mix’ of information made available.” *Id.* at 231-32, 108 S. Ct. at 983 (internal quotation marks omitted). With respect to contingent or speculative information such as preliminary merger discussions, materiality “will depend at any given time upon a balancing of both the indicated probability that the event will occur and the anticipated magnitude of the event in light of the totality of the company activity.” *Id.* at 238, 108 S. Ct. at 987 (internal quotation marks omitted); accord *Ginsburg*, 362 F.3d at

7. *See also* New York Stock Exchange Listed Company Manual § 202.03 (2014) (“If rumors or unusual market activity indicate that information on” merger negotiations “has leaked out, . . . an immediate candid statement to the public as to the state of negotiations . . . must be made directly and openly. Such statements are essential despite the business inconvenience which may be caused” (emphasis added)).

Appendix A

1302. The Supreme Court has instructed that “a factfinder will need to look to indicia of interest in the transaction at the highest corporate levels” and consider, inter alia, “board resolutions, instructions to investment bankers, and actual negotiations between principals or their intermediaries.” *Basic*, 485 U.S. at 239, 108 S. Ct. at 987. The materiality inquiry “requires delicate assessments of the inferences a ‘reasonable shareholder’ would draw from a given set of facts and the significance of those inferences to him, and these assessments are peculiarly ones for the trier of fact.” *TSC Indus., Inc. v. Northway, Inc.*, 426 U.S. 438, 450, 96 S. Ct. 2126, 2133, 48 L. Ed. 2d 757 (1976); accord *Ginsburg*, 362 F.3d at 1302.

We conclude that SLI’s discussions with Sanofi-Aventis were sufficiently advanced by January 6, 2009, when Finnerty exercised his “put” option, for a jury to find them material. By January of 2009, Charles Stiefel had met with the chief executive officer of Sanofi-Aventis to discuss the strategic fit between the two companies, and SLI had engaged Blackstone Advisory Services to facilitate a possible sale. See *Castellano*, 257 F.3d at 180, 182 n.5 (holding that tentative merger discussions had “advanced to the point that they would not have been considered immaterial as a matter of law” where the defendant company had hired an investment bank and the CEOs and CFOs of the transacting parties had “met to discuss possible structures for the transaction, as well as how the companies’ operations would fit together”). Moreover, the valuation analysis conducted by Blackstone Advisory Services had shown that the potential acquisition price could be in the range of 2.5 to 4.5 times revenue, which

Appendix A

would be of considerable magnitude for SLI shareholders. *See id.* at 185 (indicating that the anticipated magnitude of the potential transaction—such as a “doubling or tripling of the value of [shareholders’] holdings”—is probative of materiality); *Basic*, 485 U.S. at 240 n.19, 108 S. Ct. at 988 n.19 (citing approvingly to *SEC v. Shapiro*, 494 F.2d 1301, 1306-07 (2d Cir. 1974), which held that “in light of projected very substantial increase in earnings per share, negotiations [were] material, although merger still less than probable”). Under these circumstances, the jury could certainly find that by January 6, 2009, a reasonable investor would view SLI’s negotiations with Sanofi-Aventis as “significantly alter[ing] the ‘total mix’ of information made available.” *Basic*, 485 U.S. at 232, 108 S. Ct. at 983 (internal quotation marks omitted).⁸

B. Motion for new trial.

SLI also appeals the denial of its Rule 59 motion for a new trial. “We review a district court’s denial of a motion for new trial only for an abuse of discretion.” *Myers*, 640

8. Because we conclude that the omitted information in this case meets the materiality standard, we readily reject SLI’s challenge to the damages award. SLI concedes that “if the jury decides plaintiff would not have consummated the sale, it may then award the difference between the sale price and the value of the stock at a reasonable time in the future.” Appellant’s Br. at 34 (alterations in original) (quoting *Dupuy v. Dupuy*, 551 F.2d 1005, 1025 (5th Cir. 1977)). The jury here reasonably found that knowledge of the undisclosed merger negotiations would have affected Finnerty’s decision to sell. Finnerty is thus entitled to recover the difference between the price he received and the value of SLI stock under the terms of the GSK merger agreement.

Appendix A

F.3d at 1287. We also review a district court’s refusal to give a requested jury instruction for abuse of discretion. *See Lamonica v. Safe Hurricane Shutters, Inc.*, 711 F.3d 1299, 1309 (11th Cir. 2013). “An abuse of discretion is committed only when (1) the requested instruction correctly stated the law, (2) the instruction dealt with an issue properly before the jury, and (3) the failure to give the instruction resulted in prejudicial harm to the requesting party.” *Id.* (internal alteration and quotation marks omitted).

1. *Jury instruction on “put” option.*

SLI contends that the district court erred by refusing to give the following jury instruction: “With certain limited exceptions not applicable to this case, under federal law and the terms of the ESBP, [SLI] was required to purchase [Finnerty’s] shares of stock from him as soon as he exercised his irrevocable put right on January 6, 2009.” SLI claims that the district court’s evidentiary rulings—with respect to SLI’s ability to impose a “blackout”—allowed Finnerty to “create the false impression that [it] could have refused to honor Finnerty’s put election” and that scienter can be inferred from its failure to do so.⁹ The requested instruction, SLI

9. SLI does not clearly argue on appeal that the district court abused its discretion in admitting evidence concerning “blackout” periods, so we do not consider that issue. *See Willard v. Fairfield S. Co.*, 472 F.3d 817, 825 n.4 (11th Cir. 2006).

SLI does suggest, however, that the district court erred in excluding testimony that SLI was required by law to honor

Appendix A

insists, was necessary to cure the prejudice caused by this alleged misrepresentation.

Before we address the parties' arguments, a few words are in order regarding the difference between the ESBP's obligation to distribute benefits (*e.g.*, securities) to plan participants upon request and SLI's obligation to honor "put" options on the distributed securities.

A stock bonus plan, like the ESBP, is an employee compensation program, established and maintained by an employer, which distributes benefits in the form of cash or stock in the employer company. *See* 26 C.F.R. § 1.401-1(a)(2)(iii). Contributions to the plan are allocated to individual participant accounts, and benefits are distributed to plan participants or their beneficiaries according to a predetermined formula, such as upon retirement, severance, or death. *See id.* § 1.401-1(b)(1)(ii)-(iii). To qualify for certain tax-favored treatment, a stock bonus plan must meet the requirements of Internal Revenue Code § 401(a) and, in turn, § 409(h). *See* 26 U.S.C. § 401(a)(23); John D. Colombo, *Paying for Sins of the*

Finnerty's "put" exercise and that thirty-day advanced notice would have been required to impose a "blackout" period. The district court excluded this testimony because it was offered by witnesses who were not qualified as experts and because it constituted a legal opinion. This was not an abuse of discretion. U.S. law "is properly considered and determined by the court whose function it is to instruct the jury on the law; [U.S.] law is not to be presented through testimony and argued to the jury as a question of fact." *United States v. Oliveros*, 275 F.3d 1299, 1306-07 (11th Cir. 2001).

Appendix A

Master: An Analysis of the Tax Effects of Pension Plan Disqualification and a Proposal for Reform, 34 Ariz. L. Rev. 53, 56-58 (1992). Section 409(h)(1) provides that “a participant who is entitled to a distribution from the plan . . . has a right to demand that his benefits be distributed in the form of employer securities,” and that “if the employer securities are not readily tradable on an established market,” the participant “has a right to require that the employer repurchase employer securities under a fair valuation formula.” 26 U.S.C. § 409(h)(1).

Because stock bonus plans are considered defined contribution pension plans, they are also regulated by ERISA. As relevant for purposes of this appeal, ERISA restricts the ability of plan administrators to impose “blackout” periods—*i.e.*, to “suspen[d], limit[], or restrict[]” participants’ ability to “obtain distributions from the plan” for more than three consecutive business days. *See generally* 29 U.S.C. § 1021(i). It provides that no “blackout” period may take effect until at least thirty days after written notice of the “blackout” is provided to plan participants or their beneficiaries. *Id.* § 1021(i)(1)-(2). A suspension, limitation, or restriction “which occurs by reason of the application of the securities laws,” however, is exempt from the definition of “blackout” period, *id.* § 1021(i)(7)(B)(i), as well as the thirty-day notice requirement.

Significantly, ERISA’s “blackout” provisions do not affect an employer’s obligation to honor “put” options on the distributed securities. The notice requirements apply solely to suspensions, limitations, or restrictions

Appendix A

on plan participants' ability "to obtain distributions" of securities from the stock bonus plan. *Id.* § 1021(i)(7)(A). In other words, a participant can "put" securities which had previously been distributed, and the employer may be obligated to honor the "put," even during a "blackout" period. SLI is thus wrong to suggest that the ESBP's ability to impose a "blackout," with or without thirty days' advanced notice, is directly relevant to the issue of whether SLI could lawfully refuse to repurchase Finnerty's stock once Finnerty exercised his "put" option. The ability to impose a "blackout" is only indirectly relevant; *e.g.*, if SLI had imposed a "blackout" before Finnerty elected to have the stock distributed, then Finnerty would not have had the stock to "put."

SLI's argument on appeal reflects a fundamental misunderstanding of the difference between the ESBP's obligation to distribute Finnerty's benefits upon request and SLI's obligation to honor his "put" option on the distributed securities. SLI argues that the requested instruction—*i.e.*, "With certain limited exceptions not applicable to this case, under federal law and the terms of the ESBP, [SLI] was required to purchase [Finnerty's] shares of stock from him as soon as he exercised his irrevocable put right on January 6, 2009"—was necessary to dispel any notion among the jurors that "SLI could have refused to honor Finnerty's put election" after he exercised it. However, Finnerty did not argue to the jury that SLI could have declined to purchase the stock after Finnerty exercised his "put" option on January 6, 2009. Rather, Finnerty argued to the jury that SLI could have imposed a "blackout" before Finnerty elected on January

Appendix A

6, 2009, to receive a distribution of securities from the ESBP (thus preventing Finnerty from having any stock to “put”).¹⁰ Specifically, Finnerty’s counsel told the jury at closing:

You heard testimony . . . that there was a period of time, from the end of the fiscal year until the new price came out, that they could not sell their stock Nobody could take a distribution When [the Stiefels] started considering the sale of this company, why couldn’t they do that?

Tr. 555 at 47-48 (emphasis added).

Having carefully reviewed the record, we are not persuaded that the jury was misled into believing that SLI could have lawfully declined to buy back the securities from Finnerty after it was “put.” Finnerty presented no evidence and no argument to the jury with respect to whether SLI had such a legal obligation. The only evidence introduced by either party relevant to SLI’s legal obligation to Finnerty once he exercised his “put” was the testimony elicited by SLI that it was “required to” honor Finnerty’s “put” option and repurchase Finnerty’s shares after the option was exercised and the conflicting evidence

10. Finnerty’s argument was a comment on the testimony that he had elicited that SLI had on occasion suspended distributions to ESBP participants. SLI presented evidence to the contrary—*e.g.*, to the effect that SLI could not have imposed a “blackout” because it did not have time to give the required thirty days’ notice and because it could not give the reasons for the “blackout” without publicly disclosing the sensitive merger negotiations.

Appendix A

as to whether SLI could have imposed a “blackout.”¹¹ Thus, we are not persuaded that the jury was laboring under any misimpression with respect to whether SLI had a legal obligation to buy the stock once Finnerty exercised his “put”; we are not persuaded that there was a misimpression that required a correction. Our review of the entirety of the jury instructions, the arguments of counsel, and the relevant parts of the record leaves

11. SLI argues on appeal that it could not have imposed a suspension on benefits distributions without complying with ERISA’s thirty-day notice requirement for “blackout” periods, but it does not clearly challenge in its briefs on appeal any failure to give an instruction to that effect. Thus, there is no preserved, reversible error based on a refusal by the district court to charge the jury with respect to whether SLI could have imposed a “blackout” period.

Moreover, even if SLI had preserved error in that regard, SLI elicited testimony at trial that it could not impose a “blackout” in connection with the merger discussions because it did not “have 30 days notice” and could not “disclose the reasons why,” and Finnerty never argued to the jury that ERISA’s thirty-day notice requirement did not apply in this case. Because Charles Stiefel and his sons decided on November 26, 2008, to “move on” the sale, a reasonable jury could find that SLI could have voluntarily given the notice of a “blackout” more than thirty days before Finnerty elected to take his distribution from ESPB and elected to exercise his “put.”

Thus, even if SLI had preserved error with respect to an instruction on the “blackout” provisions, the error would have been harmless. *Cf. Conroy v. Abraham Chevrolet-Tampa, Inc.*, 375 F.3d 1228, 1235 (11th Cir. 2004) (holding that failure to give a requested instruction was not reversible error where the requesting party had an opportunity to argue the substance of the instruction to the jury).

Appendix A

us confident that the failure of the district court to give the requested instruction, even if a correct statement of the law, had no effect on the verdict. Because SLI has demonstrated no prejudice from the district court's refusal to give the instruction, we find no abuse of discretion here.¹²

12. For this reason, we need not decide whether the requested instruction is a correct statement of the law, a matter about which there is some doubt. For example, the request indicated that SLI had an absolute obligation to honor the “put” and purchase the stock regardless of other circumstances. However, it is at least arguable that SLI’s inside information of the material merger potential is a circumstance mitigating any such obligation. *See* 26 C.F.R. § 54.4975-7(b)(12)(ii) (providing that “[t]he period during which a put option is exercisable does not include any time when a [participant] is unable to exercise it because the party bound by the put option is prohibited from honoring it by applicable Federal or state law”). Further, it is at least arguable that SLI could have avoided any repurchase obligation by disclosing to Finnerty in confidence and giving him the opportunity to withdraw through mutual rescission of the “put” election. *Cf. Smith*, 891 F.2d at 1574; *Jordan*, 815 F.2d at 431. Finally, it is at least arguable that the requested instruction is misleading because it suggests an absolute obligation to buy the stock; we think such an obligation is at least arguably qualified by the fact that SLI could have declared a “blackout” and thereby prevented the distribution of stock to Finnerty, thus also preventing the occurrence of Finnerty’s “put.” For these reasons, there is at least some doubt about whether SLI’s requested instruction would be misleading.

Both our decision and the fact that SLI in this case actually had the required thirty days to notify with respect to a “blackout,” *see supra* note 11, make it unnecessary for us to decide whether SLI’s inside information means that the “blackout” thirty-day notice requirement is inapplicable under 29 U.S.C. § 1021(i)(7)(B)(i) (excepting from the definition of “blackout” a suspension

*Appendix A***2. *SLI's remaining arguments.***

There is little merit to SLI's remaining contentions. We reject summarily its challenge to the district court's instruction on scienter. If an instruction accurately reflects the law, the district court is "afforded wide discretion as to the style and wording employed"; we will reverse only "where we are left with a substantial and ineradicable doubt as to whether the jury was properly guided in its deliberations." *State Farm Fire & Cas. Co. v. Silver Star Health & Rehab*, 739 F.3d 579, 585 (11th Cir. 2013) (internal quotation marks omitted). SLI does not argue that the district court's scienter instruction misstated the law. Rather, SLI argues that the instruction could have been read by jurors as setting forth alternative definitions of scienter: one requiring intent to "deceive, manipulate, or defraud," and the other improperly requiring only "kn[owledge] of the existence of material facts that were not disclosed." But SLI's own counsel made it clear to the jury that the instruction described two different kinds of securities fraud—a misrepresentation and an omission—and that "[b]oth of those things must be done with an intent to deceive, manipulate, or defraud." Under these circumstances, we are not left with "a substantial and ineradicable doubt" as to whether the instruction failed to require a finding of a mental state embracing intent to deceive, manipulate, or defraud. *Id.* (internal quotation marks omitted).¹³

of distributions which occur "by reason of the application of the securities laws").

13. Moreover, even if the jury instruction could be read as setting forth alternative definitions of scienter, as SLI urges, our conclusion would not change because the purported alternative

Appendix A

SLI's argument that the district court erred in rejecting its proposed instruction that "[a] person who believes that his alleged misrepresentation or omission is in the corporation's best interests does not have the requisite state of mind, or scienter, to violate Section 10(b)" is equally meritless. SLI relies on *United States v. D'Amato*, which holds that "[m]ail fraud cannot be charged against a corporate agent who in good faith believes that his or her (otherwise legal) misleading or inaccurate conduct is in the [victim] corporation's best interests." 39 F.3d 1249, 1257 (2d Cir. 1994). *D'Amato* is inapposite here. The context in *D'Amato* was that the alleged wrongdoer believed in good faith that his actions were in the best interest of the alleged victim. By contrast, in this case, the "corporation's best interests" are not at all aligned with the interests of the victim plaintiff.

definition that SLI challenges accurately conveyed the law. The relevant phrase provided: "knew of the existence of material facts that were not disclosed although the Defendant knew that knowledge of those facts would be necessary to make the Defendant's other statements not misleading." Jury Instructions at 12-13 (emphasis added). This is consistent with our cases holding that the scienter requirement of Rule 10b-5 may be satisfied by a showing that the defendant's conduct was "an extreme departure from the standards of ordinary care" and "present[ed] a danger of misleading buyers or sellers which is either known to the defendant or is so obvious that the defendant must have been aware of it." *Mizzaro v. Home Depot, Inc.*, 544 F.3d 1230, 1238 (11th Cir. 2008) (internal quotation marks omitted).

Appendix A

III. Conclusion.

For the foregoing reasons, the judgment of the district court is

AFFIRMED.¹⁴

14. We deem SLI's appeal of the costs award waived because SLI "failed to develop the argument or to offer any citation to the record in support of it." *Carmichael v. Kellogg, Brown & Root Serv.*, 572 F.3d 1271, 1283 (11th Cir. 2009).

Appellants' motion to strike the *amicus curiae* brief filed by the Securities and Exchange Commission, which was carried with the case, is denied.

**APPENDIX B — FINAL JUDGMENT OF THE
UNITED STATES DISTRICT COURT FOR THE
SOUTHERN DISTRICT OF FLORIDA,
DATED JULY 9, 2012**

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF FLORIDA

CASE NO. 09-21871-CV-KING/McALILEY

TIMOTHY FINNERTY,

Plaintiff,

vs.

STIEFEL LABORATORIES, INC.,
a Delaware Corporation, *et al.*,

Defendants.

FINAL JUDGMENT

This action was tried by a jury with Judge James Lawrence King presiding. On May 16, 2012, the jury rendered a verdict for Plaintiff in the amount of \$1,502,484.90. (*See* DE #515). After stipulating to the dismissal of remaining Counts 1 and 2 set to be tried June 25, 2012 (DE #524), Plaintiff filed a Motion for Entry of Judgment (DE #527), seeking the verdict amount, plus pre-judgment interest pursuant to Section 687.01 of the Florida Statutes. Defendant filed a Response (DE #530) on June 27, 2012, opposing Plaintiffs request for pre-judgment interest. Plaintiff replied on June 28, 2012 (DE #532).

Appendix B

Upon careful consideration of the pleadings and pursuant to Federal Rules of Civil Procedure 54 and 58, final judgment is hereby entered in favor of Plaintiff Timothy Finnerty and against Defendants Charles Stiefel and Stiefel Laboratories, Inc. Accordingly, it is hereby **ORDERED, ADJUDGED, and DECREED** that Timothy Finnerty recover from Charles Stiefel and Stiefel Laboratories, Inc. \$1,502,484.90 in damages and \$263,523.20 in pre-judgment interest, for a total of \$1,766,018.10, plus \$195.53 per day from June 25, 2012 to the date of this Final Judgment in prejudgment interest, for which let execution issue.

Appropriate costs, if any, will be taxed by separate motion and order. Post-judgment interest shall accrue pursuant to 28 U.S.C. § 1961.

Any pending motions are hereby denied as moot.

DONE and **ORDERED** in Chambers at the James Lawrence King Federal Justice Building and United States Courthouse, Miami, Florida, dated this 9th day of July, 2012.

/s/ James Lawrence King
James Lawrence King
United States District Judge
Southern District of Florida

**APPENDIX C — ORDER DENYING PETITION
FOR REHEARING OF THE UNITED STATES
COURT OF APPEALS FOR THE ELEVENTH
CIRCUIT, FILED SEPTEMBER 8, 2014**

IN THE UNITED STATES COURT OF APPEALS
FOR THE ELEVENTH CIRCUIT

No. 12-13947-DD

TIMOTHY FINNERTY,

Plaintiff-Appellee,

versus

STIEFEL LABORATORIES, INC., a Delaware
corporation, CHARLES W. STIEFEL,

Defendants-Appellants,

No. 12-15060-DD

TIMOTHY FINNERTY,

Plaintiff-Appellee,

versus

STIEFEL LABORATORIES, INC.,
a Delaware corporation, CHARLES W. STIEFEL,

Defendants-Appellants,

33a

Appendix C

No. 12-15642-DD

TIMOTHY FINNERTY,

Plaintiff-Appellee,

versus

STIEFEL LABORATORIES, INC., a Delaware
corporation, CHARLES W. STIEFEL,

Defendants-Appellants,

Appeal from the United States District Court
for the Southern District of Florida

ON PETITION(S) FOR REHEARING AND
PETITION(S) FOR REHEARING EN BANC

BEFORE: ANDERSON, Circuit Judge, and MOODY*
and SCHLESINGER,** District Judges.

PER CURIAM:

The Petition(s) for Rehearing are DENIED and no Judge
in regular active service on the Court having requested
that the Court be polled on rehearing en banc (Rule 35,

* Honorable James S. Moody, Jr., United States District
Judge for the Middle District of Florida, sitting by designation.

** Honorable Harvey E. Schlesinger, United States District
Judge for the Middle District of Florida, sitting by designation.

34a

Appendix C

Federal Rules of Appellate Procedure), the Petition(s) for Rehearing En Banc are DENIED.

ENTERED FOR THE COURT:

s/ R. Lanier Anderson

UNITED STATES CIRCUIT JUDGE

**APPENDIX D — STATUTORY AND RULE
PROVISIONS INVOLVED**

SECURITIES EXCHANGE ACT, SECTION 10(b)

15 U.S.C. § 78j Manipulative and deceptive devices

It shall be unlawful for any person, directly or indirectly, by the use of any means or instrumentality of interstate commerce or of the mails, or of any facility of any national securities exchange—

(a)(1) To effect a short sale, or to use or employ any stop-loss order in connection with the purchase or sale, of any security other than a government security, in contravention of such rules and regulations as the Commission may prescribe as necessary or appropriate in the public interest or for the protection of investors.

(2) Paragraph (1) of this subsection shall not apply to security futures products.

(b) To use or employ, in connection with the purchase or sale of any security registered on a national securities exchange or any security not so registered, or any securities-based swap agreement¹ any manipulative or deceptive device or contrivance in contravention of such rules and regulations as the Commission may prescribe as necessary or appropriate in the public interest or for the protection of investors.

(c)(1) To effect, accept, or facilitate a transaction involving the loan or borrowing of securities in

1. So in original. Probably should be followed by a comma.

Appendix D

contravention of such rules and regulations as the Commission may prescribe as necessary or appropriate in the public interest or for the protection of investors.

(2) Nothing in paragraph (1) may be construed to limit the authority of the appropriate Federal banking agency (as defined in section 1813 (q) of title 12), the National Credit Union Administration, or any other Federal department or agency having a responsibility under Federal law to prescribe rules or regulations restricting transactions involving the loan or borrowing of securities in order to protect the safety and soundness of a financial institution or to protect the financial system from systemic risk.

Rules promulgated under subsection (b) of this section that prohibit fraud, manipulation, or insider trading (but not rules imposing or specifying reporting or recordkeeping requirements, procedures, or standards as prophylactic measures against fraud, manipulation, or insider trading), and judicial precedents decided under subsection (b) of this section and rules promulgated thereunder that prohibit fraud, manipulation, or insider trading, shall apply to security-based swap agreements to the same extent as they apply to securities. Judicial precedents decided under section 77q(a) of this title and sections 78i, 78o, 78p, 78t, and 78u–1 of this title, and judicial precedents decided under applicable rules promulgated under such sections, shall apply to security-based swap agreements to the same extent as they apply to securities.

Appendix D

Securities Exchange Rule, Section 10b-5

**17 C.F.R. § 240.10b-5 Employment of manipulative
and deceptive devices.**

It shall be unlawful for any person, directly or indirectly, by the use of any means or instrumentality of interstate commerce, or of the mails or of any facility of any national securities exchange,

(a) To employ any device, scheme, or artifice to defraud,

(b) To make any untrue statement of a material fact or to omit to state a material fact necessary in order to make the statements made, in the light of the circumstances under which they were made, not misleading, or

(c) To engage in any act, practice, or course of business which operates or would operate as a fraud or deceit upon any person, in connection with the purchase or sale of any security.